Medi Caps Ltd
Incorporated in 1983, Medi-Caps Ltd is in the business of real estate and pharmaceuticals[1]
- Market Cap ₹ 29.0 Cr.
- Current Price ₹ 23.2
- High / Low ₹ 37.0 / 20.3
- Stock P/E
- Book Value ₹ 89.4
- Dividend Yield 0.00 %
- ROCE -9.19 %
- ROE -9.21 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.26 times its book value
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -26.3% over past five years.
- Company has a low return on equity of -4.34% over last 3 years.
- Earnings include an other income of Rs.6.47 Cr.
- Company has high debtors of 203 days.
- Working capital days have increased from 409 days to 598 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.11 | 42.97 | 44.04 | 53.70 | 51.79 | 43.05 | 57.42 | 69.87 | 49.37 | 27.35 | 25.48 | 12.45 | 16.32 | |
| Sales growth | -3.68% | +19.00% | +2.49% | +21.93% | -3.56% | -16.88% | +33.38% | +21.68% | -29.34% | -44.60% | -6.84% | -51.14% | +3.95% |
| 36.19 | 40.36 | 42.43 | 51.53 | 47.07 | 49.80 | 46.45 | 59.80 | 44.18 | 27.35 | 27.28 | 21.86 | 20.94 | |
| Operating Profit | -0.08 | 2.61 | 1.61 | 2.17 | 4.72 | -6.75 | 10.97 | 10.07 | 5.19 | 0.00 | -1.80 | -9.41 | -4.62 |
| OPM % | -0.22% | 6.07% | 3.66% | 4.04% | 9.11% | -15.68% | 19.10% | 14.41% | 10.51% | 0.00% | -7.06% | -75.58% | -28.31% |
| 1.29 | 0.68 | 2.02 | 1.07 | 2.73 | 2.86 | 1.77 | 1.95 | 1.49 | 0.48 | 2.73 | 8.21 | 6.47 | |
| Interest | 0.66 | 0.06 | 0.10 | 0.10 | 0.13 | 0.12 | 0.10 | 0.11 | 0.13 | 0.04 | 0.05 | 0.02 | 0.00 |
| Depreciation | 1.81 | 1.80 | 1.81 | 1.79 | 1.82 | 1.83 | 1.52 | 1.81 | 1.74 | 1.69 | 1.72 | 1.81 | 1.88 |
| Profit before tax | -1.26 | 1.43 | 1.72 | 1.35 | 5.50 | -5.84 | 11.12 | 10.10 | 4.81 | -1.25 | -0.84 | -3.03 | -0.03 |
| Tax % | 63.49% | 39.16% | 20.35% | 14.81% | 2.18% | 0.17% | -0.09% | 0.10% | 63.62% | 80.00% | -32.14% | 0.66% | |
| -2.06 | 0.86 | 1.37 | 1.15 | 5.39 | -5.85 | 11.13 | 10.08 | 1.76 | -2.24 | -0.57 | -3.04 | -0.05 | |
| EPS in Rs | -1.65 | 0.69 | 1.10 | 0.92 | 4.32 | -4.69 | 8.93 | 8.08 | 1.41 | -1.80 | -0.46 | -2.44 | -0.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | -26% |
| 3 Years: | -37% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 99% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -11% |
| 3 Years: | -20% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -1% |
| 3 Years: | -4% |
| Last Year: | -9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
| Reserves | 68.94 | 69.80 | 76.62 | 77.75 | 83.13 | 78.48 | 92.24 | 103.79 | 106.10 | 108.51 | 108.81 | 99.14 | 98.97 |
| 0.81 | 0.08 | 0.09 | 0.17 | 0.12 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 7.00 | 10.68 | 8.19 | 10.52 | 10.89 | 4.20 | 10.11 | 14.09 | 7.42 | 6.31 | 4.14 | 3.85 | 2.88 | |
| Total Liabilities | 89.22 | 93.03 | 97.37 | 100.91 | 106.61 | 95.21 | 114.82 | 130.35 | 125.99 | 127.29 | 125.42 | 115.46 | 114.32 |
| 58.05 | 56.41 | 62.14 | 61.03 | 59.80 | 57.30 | 58.12 | 59.31 | 58.91 | 58.65 | 57.18 | 56.29 | 53.92 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.97 | 0.54 | 0.24 | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 |
| Investments | 5.43 | 6.74 | 7.83 | 11.18 | 16.35 | 21.97 | 29.41 | 30.67 | 32.07 | 38.38 | 43.04 | 34.82 | 38.43 |
| 25.74 | 29.88 | 27.40 | 28.70 | 30.46 | 14.97 | 26.75 | 40.13 | 35.01 | 30.26 | 25.12 | 24.35 | 21.97 | |
| Total Assets | 89.22 | 93.03 | 97.37 | 100.91 | 106.61 | 95.21 | 114.82 | 130.35 | 125.99 | 127.29 | 125.42 | 115.46 | 114.32 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.05 | 2.59 | 4.02 | 4.20 | 5.96 | 4.63 | 15.32 | 7.02 | -6.08 | 6.94 | 5.07 | -7.02 | |
| -6.97 | -1.47 | 2.57 | -4.09 | -5.75 | -5.80 | -9.70 | -4.08 | -2.56 | -7.73 | -4.98 | 7.11 | |
| 0.00 | -0.73 | -5.76 | 0.08 | -0.05 | -0.06 | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | 0.08 | 0.39 | 0.83 | 0.20 | 0.16 | -1.23 | 5.56 | 2.95 | -8.64 | -0.79 | 0.09 | 0.09 |
| Free Cash Flow | 6.58 | 2.43 | 9.11 | 3.51 | 5.37 | 3.38 | 13.06 | 4.23 | -7.24 | 6.59 | 4.74 | -7.87 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -9,750% | 120% | 270% | 202% | 128% | -69% | 140% | 70% | -58% | -267% | 74% |
Ratios
Consolidated / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87.33 | 82.48 | 74.09 | 88.57 | 90.56 | 37.39 | 40.62 | 52.61 | 62.55 | 144.40 | 125.92 | 202.88 |
| Inventory Days | 265.71 | 257.13 | 230.21 | 148.16 | 163.52 | 75.29 | 83.45 | 156.60 | 121.72 | 243.05 | 120.79 | 209.59 |
| Days Payable | 66.33 | 101.86 | 75.75 | 90.99 | 96.26 | 26.94 | 76.61 | 154.35 | 48.72 | 77.49 | 59.64 | 34.22 |
| Cash Conversion Cycle | 286.71 | 237.75 | 228.56 | 145.73 | 157.82 | 85.74 | 47.46 | 54.85 | 135.55 | 309.96 | 187.06 | 378.25 |
| Working Capital Days | 184.07 | 154.26 | 147.11 | 113.17 | 127.42 | 84.70 | 65.41 | 87.66 | 200.50 | 324.16 | 304.12 | 598.07 |
| ROCE % | -0.69% | 1.81% | 1.48% | 1.56% | 5.77% | -6.58% | 11.59% | 8.78% | 3.70% | -1.17% | -2.12% | -9.19% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees on Roll Count ・Standalone data |
|
|||||||
| Pharma Segment Revenue Share of Consolidated Revenue % |
||||||||
| Foreign Exchange Earnings from Exports Rs. Lakhs ・Standalone data |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Extract of unaudited standalone and consolidate financial results of the company for the quarter/half year ended 30.09.2026 published in free press English edition and choutha …
-
Submission Of Unaudited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended 30.09.2026
- Board approved unaudited Q2/H1 FY2026 results on 4 Nov 2026; consolidated loss was Rs 232.12 lakh.
-
Board Meeting Outcome for Submission Of Unaudited Standalone & Consolidated Financial Result For The Quarter And Half Year Ended 30.09.2026
- Board approved unaudited standalone and consolidated results for quarter and half-year ended 30 September 2026.
-
Board Meeting Intimation for (Serial No. 03/2026-27) Of The Company, Scheduled To Be Held On Wednesday, 04Th Day Of November, 2026 Pursuant To Regulation 29 Of SEBI (LODR) Regulations, 2015.
- Board meeting on 4 Nov 2026 to approve Q2 FY27 standalone and consolidated unaudited results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Certificate for Compliance under Reg. 74(5) of SEBI (D.P.) Regulation 2018 for the quarter ended 30.09.2026
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
MCL operates in real estate as a parent company and pharma division through its wholly owned subsidiary. The company entered the real estate segment for city centric developments by way of Land acquisition and developing premium residential and commercial properties. It has almost completed its first project Medicaps Business Park and also sold ~50% of shops in the project